Geron (GERN) Debt-to-Equity : 0.35 (As of Dec. 2023)

View and export this data going back to 1996. Start your Free Trial

What is Geron Debt-to-Equity?

Geron's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $47.84 Mil. Geron's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $38.06 Mil. Geron's Total Stockholders Equity for the quarter that ended in Dec. 2023 was $247.95 Mil. Geron's debt to equity for the quarter that ended in Dec. 2023 was 0.35.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Geron's Debt-to-Equity or its related term are showing as below:

GERN' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.02 Med: 0.35 Max: 0.7
Current: 0.35

During the past 13 years, the highest Debt-to-Equity Ratio of Geron was 0.70. The lowest was 0.02. And the median was 0.35.

GERN's Debt-to-Equity is ranked worse than
68.56% of 1072 companies
in the Biotechnology industry
Industry Median: 0.145 vs GERN: 0.35

Geron Debt-to-Equity Historical Data

The historical data trend for Geron's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Geron Debt-to-Equity Chart

Geron Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Equity

Get a 7-Day Free Trial

0.02

0.14

0.44

0.70

0.35

Geron Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Debt-to-Equity	Get a 7-Day Free Trial															0.70	0.17	0.19	0.19	0.35

Competitive Comparison of Geron's Debt-to-Equity

For the Biotechnology subindustry, Geron's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Geron's Debt-to-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Geron's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Geron's Debt-to-Equity falls into.

Geron Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Geron's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(47.842	+	38.057)	/	247.949
	=	0.35

Geron's Debt to Equity Ratio for the quarter that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(47.842	+	38.057)	/	247.949
	=	0.35

Geron (NAS:GERN) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Geron Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Geron's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Geron (GERN) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Geron Corp (NAS:GERN) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

GON:Germany

Address

919 East Hillsdale Boulevard, Suite 250, Foster City, CA, USA, 94404

Website

https://www.geron.com

Geron Corp is a clinical-stage biopharmaceutical company focused on the research and development of cancer treatments. The company's leading drug in development, Imelstat, is being tested for the treatment of myelodysplastic syndromes, which are disorders of the blood, and myelofibrosis, which is a rare blood cancer affecting bone marrow. The company earns revenue through collaboration agreements, milestones, royalties, and licensing arrangements. Geron possesses global rights to this drug. the company operates as a single segment, the development of therapeutic products for oncology.

Executives

Michelle Robertson	officer: EVP, Chief Financial Officer	C/O MOMENTA PHARMACEUTICALS, INC., 301 BINNEY STREET, CAMBRIDGE MA 02142
Elizabeth G. O'farrell	director	932 SOUTHWOOD BLVD., INCLINE VILLAGE NV 89451
Scott Alan Samuels	officer: EVP, Chief Legal Officer	919 E. HILLSDALE BLVD., SUITE 250, FOSTER CITY CA 94404
V Bryan Lawlis	director
Susan Molineaux	director	C/O CALITHERA BIOSCIENCES, INC., 343 OYSTER POINT BLVD., SUITE 200, SOUTH SAN FRANCISCO CA 94080
John A Scarlett	director, officer: Chief Executive Officer	C/O GERON CORPORATION, 230 CONSTITUTION DRIVE, MENLO PARK CA 94025
Andrew J Grethlein	officer: EVP, Technical Operations	651 GATEWAY BLVD STE 950, SOUTH SAN FRANCISCO CA 94080
Olivia Kyusuk Bloom	officer: Controller, Chief Acctg Off	C/O GERON CORP, 230 CONSTITUTION DRIVE, MENLO PARK CA 94025
John F Mcdonald	director	C/O GERON CORPORATION, 919 EAST HILLSDALE BLVD., SUITE 250, FOSTER CITY CA 94404
Faye Feller	officer: EVP, Chief Medical Officer	919 EAST HILLSDALE BOULEVARD, SUITE 250, FOSTER CITY CA 94404
Anil Kapur	officer: EVP, Corp Strategy & CCO	275 MADISON AVE, SUITE 702, NEW YORK NY 10016
Melissa Kelly	officer: VP, Oncology	230 CONSTITUTION DRIVE, MENLO PARK CA 94025
Dawn Carter Bir	director	C/O REATA PHARMACEUTICALS, INC., 2801 GATEWAY DRIVE, SUITE 150, IRVING TX 75063
Aleksandra Rizo	officer: EVP, Chief Medical Officer	C/O GERON CORPORATION, 149 COMMONWEALTH DRIVE, MENLO PARK CA 94025
Robert J. Spiegel	director	C/O GERON CORPORATION, 230 CONSTITUTION DRIVE, MENLO PARK CA 94025